PGO0 Stock Chart & Stats
€0.05
-€0.02(-2.92%)
At close: 4:00 PM EST
€0.05
-€0.02(-2.92%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)259.00
Market Cap
€7.96M
Enterprise Value€25.06
Total Cash (Recent Filing)€392.00K
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta-2.56
Next Earnings
Feb 11, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.40
Shares Outstanding560,091,500
10 Day Avg. Volume700
30 Day Avg. Volume259
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.38
Price to Sales (P/S)17.06
P/FCF Ratio-0.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€111.75K
Bulls Say, Bears Say
Bulls Say
Revenue ImprovementRevenue growth indicates increasing commercial activity for the company’s diagnostic offering and provides a foundation for future operating leverage. If growth can persist, a larger installed customer base and higher test volumes could gradually improve the economics of the business.
Modest LeverageModest debt relative to equity reduces immediate balance-sheet pressure and limits the burden of interest and refinancing obligations. This gives the company more flexibility to direct resources toward commercialization and clinical adoption while it works toward improved profitability.
Specialized Diagnostic OfferingA focused genomic test addressing treatment and monitoring decisions gives PROGEN a clearly defined position in precision medicine. Its clinical-decision role can support differentiated adoption if healthcare providers value better patient stratification and integrate the test into routine care.
Bears Say
Severe UnprofitabilityLosses remain very large relative to revenue, with negative gross profit showing that the current commercial model is not yet covering direct costs. Persistent operating and net losses reduce financial resilience and make meaningful improvement dependent on stronger economics or substantial revenue growth.
Persistent Cash BurnNegative operating and free cash flow show that the business continues consuming cash to fund operations rather than internally financing growth. Although burn improved versus 2024, the continuing multi-year deficit raises funding risk and leaves profitability improvement essential for sustainability.
Limited Commercial ScaleSmall, volatile revenue has not yet translated into a scalable business, while the sizeable losses indicate limited operating leverage. Until test volumes and sales become materially larger and more consistent, the company may struggle to convert its specialized offering into durable earnings power.
PGO0 FAQ
What was Prostatype Genomics AB’s price range in the past 12 months?
Prostatype Genomics AB lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Prostatype Genomics AB’s market cap?
Prostatype Genomics AB’s market cap is €7.96M.
When is Prostatype Genomics AB’s upcoming earnings report date?
Prostatype Genomics AB’s upcoming earnings report date is Feb 11, 2027 which is in 145 days.
How were Prostatype Genomics AB’s earnings last quarter?
Prostatype Genomics AB released its earnings results on Aug 31, 2026. The company reported -€0.01 earnings per share for the quarter.
Is Prostatype Genomics AB overvalued?
According to Wall Street analysts Prostatype Genomics AB’s price is currently Overvalued.
Does Prostatype Genomics AB pay dividends?
Prostatype Genomics AB does not currently pay dividends.
What is Prostatype Genomics AB’s EPS estimate?
Prostatype Genomics AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Prostatype Genomics AB have?
Prostatype Genomics AB has 560,091,500 shares outstanding.
What happened to Prostatype Genomics AB’s price movement after its last earnings report?
Prostatype Genomics AB reported an EPS of -€0.01 in its last earnings report. Following the earnings report the stock price went down -3.846%.
Which hedge fund is a major shareholder of Prostatype Genomics AB?
Currently, no hedge funds are holding shares in DE:PGO0
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Prostatype Genomics AB
Prostatype Genomics AB focuses on creating, marketing, and selling sophisticated prognostic gene tests. Their primary offering, the Prostatype Test System, combines genetic expression data with key clinical measurements such as PSA levels, Gleason Score, and Tumor Stage to determine a specific P-score. This advanced diagnostic tool is built upon a vast database of prostate cancer patients, providing crucial support for patients and medical practitioners when deciding on treatment strategies. Founded in 2007, the company is headquartered in Solna, Sweden.
Technical Analysis
Immunovia AB
―
Q-linea AB
―
Acarix AB
―
Biovica International AB Class B
―
Devyser Diagnostics AB
―